FDA approves BEI's next-generation HTA (health technology assessment) system:
This article was originally published in Clinica
The US FDA has approved for sale a smaller, lighter and more transportable version of gynaecology company BEI Medical Systems' minimally invasive device for treating menorrhagia. The new system represents the next generation of the firm's Hydro ThermAblator (HTA) system, which was first approved in April 2001. It is especially suited for physicians' offices and same-day surgery centres, where space, storage and portability are primary concerns, says the Teterboro, New Jersey firm.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.